BADBIR Study Group[Corporate Author] - Search Results

Year	Number of Results
2012	1
2017	3
2018	7
2019	8
2020	5
2021	5
2022	3
2023	4
2024	2

1

Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.

Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group. Yiu ZZN, et al. JAMA Dermatol. 2022 Oct 1;158(10):1131-1141. doi: 10.1001/jamadermatol.2022.2909. JAMA Dermatol. 2022. PMID: 35791876 Free PMC article.

2

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.

Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CEM, Warren RB; BADBIR Study Group. Al-Janabi A, et al. JAMA Dermatol. 2024 Jan 1;160(1):71-79. doi: 10.1001/jamadermatol.2023.4846. JAMA Dermatol. 2024. PMID: 38055239 Free PMC article.

3

Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.

Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Grifﬁths CEM; BADBIR Study Group. Alabas OA, et al. Br J Dermatol. 2023 Apr 20;188(5):618-627. doi: 10.1093/bjd/ljad004. Br J Dermatol. 2023. PMID: 36763783

4

Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Grifﬁths CEM; BADBIR Study Group. Alabas OA, et al. Br J Dermatol. 2023 Aug 24;189(3):271-278. doi: 10.1093/bjd/ljad179. Br J Dermatol. 2023. PMID: 37226927 Clinical Trial.

5

The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology.

Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group. Yiu ZZN, et al. Br J Dermatol. 2020 Dec;183(6):981-983. doi: 10.1111/bjd.19536. Br J Dermatol. 2020. PMID: 33316094 No abstract available.

6

Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.

Al-Janabi A, Martin P, Khan AR, Foulkes AC, Smith CH, Griffiths CEM, Morris AP, Eyre S, Warren RB; BSTOP Study Group and the BADBIR Study Group. Al-Janabi A, et al. J Allergy Clin Immunol. 2023 Nov;152(5):1237-1246. doi: 10.1016/j.jaci.2023.07.011. Epub 2023 Aug 1. J Allergy Clin Immunol. 2023. PMID: 37536512 Free article.

7

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group. Mason KJ, et al. JAMA Dermatol. 2018 May 1;154(5):581-588. doi: 10.1001/jamadermatol.2018.0183. JAMA Dermatol. 2018. PMID: 29590279 Free PMC article.

8

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. JAMA Dermatol. 2021 Jan 1;157(1):66-73. doi: 10.1001/jamadermatol.2020.4202. JAMA Dermatol. 2021. PMID: 33263718 Free PMC article.

9

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group. Yiu ZZN, et al. Br J Dermatol. 2020 Aug;183(2):294-302. doi: 10.1111/bjd.18981. Epub 2020 Mar 30. Br J Dermatol. 2020. PMID: 32124442

10

Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

Lada G, Chinoy H, Talbot PS, Warren RB, Kleyn CE; BADBIR Study Group. Lada G, et al. Skin Health Dis. 2022 Jul 6;2(4):e149. doi: 10.1002/ski2.149. eCollection 2022 Dec. Skin Health Dis. 2022. PMID: 36479266 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

30 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year